Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

Inclusion criteria

• Patient has documented diagnosis of advanced solid tumor for which no standard systemic therapy exists
• Patient has normal or abnormal renal organ function
• Patient has provided written informed consent prior to any screening procedures

Exclusion criteria

• Patient needing valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat dose
• Patient received prior treatment with DAC inhibitors including panobinostat
• Patient requiring dialysis
• Patient requiring diuretics unless patient is taking potassium sparring diuretics
• Patient has acute renal failure, history of transplant, ESRD (however acceptable severe renal impaired group)
• Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.

Other protocol-defined inclusion/exclusion criteria may apply